Shares of Moderna and Merck soared on Wednesday morning after a study showed that a vaccine they produced had promising results when it comes to fighting skin cancer. A late-stage trial showed that the mRNA vaccine helped reduce the recurrence of melanoma. Sam Fazeli of Bloomberg Intelligence has more. (Source: Bloomberg)
Shares of Moderna and Merck soared on Wednesday morning after a study showed that a vaccine they produced had promising results when it comes to fighting skin cancer. A late-stage trial showed that the mRNA vaccine helped reduce the recurrence of melanoma. Sam Fazeli of Bloomberg Intelligence has more. (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/d67d89ca250eec81dd8a92b5210e3322de503fb3" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Merck, Moderna Stocks Soar After Melanoma Trial Success"></iframe>